Welcome to our dedicated page for Swk Hldgs news (Ticker: SWKH), a resource for investors and traders seeking the latest updates and insights on Swk Hldgs stock.
SWK Holdings Corp (NASDAQ: SWKH) - a leader in specialized healthcare finance - provides investors and industry stakeholders with critical updates through this centralized news hub. Track all official announcements, strategic developments, and financial disclosures from the company pioneering non-dilutive funding solutions for life science innovators.
This resource delivers verified SWKH news including earnings reports, royalty financing agreements, partnership announcements, and regulatory filings. Investors gain timely access to:
- Quarterly financial performance updates
- Strategic acquisitions and asset purchases
- Enteris BioPharma development milestones
- Portfolio company progress reports
Bookmark this page for direct access to SWK Holdings' latest press releases and market-moving developments. Our curated news collection eliminates fragmented research, providing a reliable single source for monitoring the company's healthcare finance activities and pharmaceutical sector impact.
SWK Holdings (NASDAQ: SWKH) announced its financial results for Q1 2024. The company reported a GAAP net income of $0.9 million, down from $4.6 million in Q1 2023. Adjusted non-GAAP net income for the finance receivables segment was $2.7 million, compared to $7.3 million in the same quarter last year.
As of March 31, 2024, gross finance receivables were $274.5 million, a 10.3% increase year-over-year, with an effective yield of 14.2%. Despite a $6.0 million impairment to its loan book, the company saw a 23.7% revenue increase in its finance segment to $11.5 million.
The book value per share stood at $22.46, while the non-GAAP tangible financing book value per share was $19.69. During the quarter, SWK repurchased 58,298 shares of common stock for approximately $1 million.
SWK's Enteris division signed an Option and Asset Purchase Agreement and received a low-single-digit million-dollar option fee in April 2024. The company remains focused on high-margin, strategic opportunities in the life sciences finance market.
FAQ
What is the current stock price of Swk Hldgs (SWKH)?
What is the market cap of Swk Hldgs (SWKH)?
